Scarica l'app Stockscreener
2.82
0.35%
-0.01
Dopo l'orario di chiusura:
2.82
Precedente Chiudi:
$2.83
Aprire:
$2.83
Volume 24 ore:
4,561
Relative Volume:
0.04
Capitalizzazione di mercato:
$12.85M
Reddito:
-
Utile/perdita netta:
$-2.17M
Rapporto P/E:
-0.1626
EPS:
-17.3434
Flusso di cassa netto:
$-4.82M
1 W Prestazione:
-1.74%
1M Prestazione:
+6.82%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.81
$2.88
Intervallo di 1 settimana:
$2.81
$2.98
Portata 52W:
$1.89
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
2.82 | 12.90M | 0 | -2.17M | -4.82M | -17.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newcelx Ltd Borsa (NCEL) Ultime notizie
Should You Buy NewcelX AG (NCEL) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
NLSPW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NCEL | NewcelX Ltd. Ordinary Shares Stock Data, Price & News - Quiver Quantitative
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy - Finviz
NewcelX Cites Peer-Reviewed Mazindol Data as It Advances CVR-Linked Asset Talks - TipRanks
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences - Finviz
NewcelX Updates Corporate Presentation as It Sharpens Focus on Type 1 Diabetes Cell Therapies - TipRanks
NewcelX Announce Positive Results from International Collaborati - GuruFocus
NewcelX Reports Positive International Study Results on Biomaterial-Based Islet Delivery for Type 1 Diabetes - TipRanks
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression - marketscreener.com
Newcelx Ltd. Announces Positive Results from International Collaborative Study - marketscreener.com
NLS Pharmaceutics Announces Reverse Share Split and Name Change Amid Merger - MSN
NewCelX Appoints EY as New Auditor Following Merger - MSN
NewcelX appoints Swiss pharma executive to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX adds Swiss diabetes leader to advisory board to steer IsletRx program - MSN
NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board - marketscreener.com
NewcelX Adds Swiss Diabetes Leader to Advisory Board to Steer IsletRx Program - TipRanks
NewcelX appoints Swiss pharma executive to scientific advisory board - Investing.com
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - Barchart.com
Should I buy NewcelX Ltd. (NCEL) - Zacks Investment Research
What is the current Price Target and Forecast for NewcelX Ltd. (NCEL) - Zacks Investment Research
NewcelX Ltd. (NCEL) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Newcelx Ltd. Share Price (NCEL.US) - London South East
NewcelX Strengthens IP Portfolio with Chinese Patent Publication - TipRanks
NewcelX strengthens IP portfolio with Chinese patent publication - MSN
NewcelX patent for neurological disease treatments published in China - Investing.com
NewcelX patent for neurological disease treatments published in China By Investing.com - Investing.com Canada
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Nasdaq
NewcelX Ltd. (NCEL) -8.5% in After-hours: Decline Amid Routine Trading Conditions - Stocks Telegraph
NLSP SEC FilingsNls Pharmaceutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - Aktiellt
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board (PR Newswire) - Aktiellt
NewcelX Ltd.Ordinary Shares (NQ: NCEL - Markets Financial Content
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer) | NLSP SEC FilingForm 6-K - Stock Titan
NewcelX appoints ALS specialist to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX appoints ALS specialist to scientific advisory board - Investing.com
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - Finviz
NewcelX Appoints Renowned Neurologist to Strengthen Scientific Advisory Board - TipRanks
Price to sales ratio of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Press Release: NewcelX Announces Scientific Leadership With the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - 富途牛牛
NewcelX Ltd. (NCEL) - Zacks Investment Research
NLS Pharmaceutics to execute 1-for-10 reverse share split - MSN
NewcelX Ltd. (NCEL) company profile and facts - Yahoo Finance UK
NewcelX Announces New CFO Appointment Following Merger - MSN
NewcelX Ltd. (NCEL) interactive stock chart - Yahoo Finance UK
NewcelX Ltd. (NCEL) Stock Forum & Discussion - Yahoo! Finance Canada
NewcelX Ltd (NCEL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
NewcelX Ltd (NCEL) Stock Earnings Transcripts - GuruFocus
NewcelX appoints Omri Hagai as chief financial officer, effective December 10 By Investing.com - Investing.com Australia
Newcelx Ltd Azioni (NCEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):